December 2024
The Europe cell culture media market is estimated to grow from USD 771.2 million in 2022 to reach an estimate of USD 1,453.2 million by 2032, at a 6.29% CAGR between 2023 and 2032.
Unlock Infinite Advantages: Subscribe to Annual Membership
The culture medium is the powerhouse that contains several nutrients that aid in the development, proliferation, maintenance, and storage of microbial and other cell types, such as stem cells or other cell lines.
A growth medium, often referred to as a cell culture medium, is a solid, liquid, or semisolid medium that contains a variety of ingredients and nutrients and is used to support the growth, multiplication, maintenance, and storage of microorganisms, plant cells, mammalian cells, and other cell lines.
The european market for regenerative therapeutics is anticipated to be significantly impacted by the COVID-19 pandemic. In a 2020 study that appeared in the European Respiratory Journal, researchers found that novel therapeutic approaches, such as cell-based therapies, particularly those that use mesenchymal stem cells, have proven to be secure and effective in treating patients with Acute Respiratory Distress Syndrome (ARDS). The development of stem cell-based therapies for the management of SARS-CoV-2 illness has received increased attention. The market under consideration is anticipated to see a significant impact during the pandemic as a result of the aforementioned factors.
We can conclude, the COVID-19 pandemic has generated several prospects for tissue and cell culture, regenerative medicine, and enhancing clinical trial outcomes in the shortest amount of time. Therefore, it is anticipated that the market for cell culture medium would experience significant growth during the pandemic era and will forecast an accelerating growth rate throughout the following years to improve disease diagnostics and therapies.
Cell culture technology has become a crucial component of vaccine production in the pharmaceutical sector. The development of vaccinations against polio, rotavirus, hepatitis, smallpox, chickenpox, and rubella is made easier by cell culture technologies. Additionally, the use of cell-based flu vaccinations has been allowed by the US and numerous European countries.
In the past, viruses were harvested and grown inside chicken eggs to create vaccinations, but this procedure was time-consuming. The cell-culture approach is currently being used to generate vaccines, which is far more effective than the conventional approach. The new cell-culture process makes it possible to produce a lot of vaccines quickly. Additionally, we can say that the vaccines made utilizing the cell-culture approach have a longer shelf life.
The high cost of tissue engineering and regenerative medicine restrains the market's expansion for cell culture media. Due to the monopolistic environment created by the limited supply of tissue engineering and regenerative medicine, the developing tissue engineering sector has difficulties. As there is less competition among suppliers, these services result in increased costs.
An artificial environment where biological cells are permitted to interact or develop with their surroundings is referred to as three-dimensional cell culture. Compared to cells grown in a 2D environment, those in a 3D environment tend to undergo larger physiological and morphological alterations. Researchers claim that this cellular makeup not only boosts gene expression but also cell-cell communication.
Market Scope and Categorization
The Europe cell culture media market was valued at $498.4 million in 2018 and is projected to reach $1,316.8 million by 2030, growing at a CAGR of 8.5% from 2021 to 2030. Liquid Culture Media was the highest contributor to this market, with $277.8 million in 2018, and is anticipated to reach $722.1 million by 2030.
Serum-free media are media designed to grow a specific cell type or perform a specific application in the absence of serum.
Due to the growing advancements in the fields of gene therapy and cell therapy, pharmaceutical, and biotechnology companies dominate the global market for cell culture media.
Europe is one of the top markets for cell and gene therapy, accounting for the second largest position internationally, with France and the United Kingdom leading the way. France is the European scaffold technology, cell culture, and media market leader. France's dominance was also dictated by the world's leading biotech and research hubs that are currently active in gene and cell therapy. Aside from that, the French government has resolved to boost gene therapy development by easing the acceptance of clinical trials since it was first described in human genome maps in 1990-92. Furthermore, the government encourages the collaboration of small gene therapy research facilities and hospitals, which encourages industry partners to invest in gene therapy initiatives.
Launches | Partnerships/ Collaborations/ Agreement |
In October 2021, Thermo Fisher Scientific Inc. today announced the launch of Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, a GMP-manufactured cell culture medium that supports large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells. | In June 2020, Corning Incorporated announced the launch of Corning Matrigel matrix-3D plates, pre-dispensed with Matrigel matrix to provide a more consistent and convenient, ready-to-use cell culture option to support organoid and spheroid culture models. |
December 2024
December 2024
December 2024
November 2024